Authors


Nicole Shonka, MD

Latest:

Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain

Brain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.


Susan R. Rheingold, MD

Latest:

Pediatric Acute Lymphoblastic Leukemia

ONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia. 


Alan N. Peiris, MD

Latest:

Monitoring for Thyroid Cancer Recurrence

Alan N. Peiris, MD spoke with ONCOLOGY about guidelines and strategies for treating patients who have had thyroid cancer. 


Yuly A. Remolina-Bonilla, MD

Latest:

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma

Francisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.


Raul R. Trejo-Rosales, MD

Latest:

What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?


Bruno Saldivar-Oviedo

Latest:

What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?


Seth Augenstein

Latest:

Black, Elderly Patients Less Likely to Receive Treatment for Lung Cancer

About a fifth of patients with lung cancer in the United States receive no treatment at all, while approximately 6 in 10 receive the minimal treatments recommended by the National Comprehensive Cancer Network.


Joanna Pangilinan, PharmD, BCOP

Latest:

2019 World Conference Of Lung Cancer Round-Up

Five notable abstracts from the 2019 World Conference on Lung Cancer (WCLC).


Luke Bidikov, MD

Latest:

67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential

STUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.


Paul Maroni, MD

Latest:

Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate Cancer

This is the case of a man, aged 56 years, who presented with urinary intermittency, frequency, urgency, and dysuria 5 months after undergoing focal laser ablation (FLA) of Gleason 3 + 4 = 7 prostate cancer (PC).


Simon Kim, MD, MPH

Latest:

67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential

STUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.


Shaheed Merani, MD, PhD, FRCSC

Latest:

Biliary Cancer: Current Multimodality Treatment and Future Directions

Clinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.


Luciano M. Vargas, MD

Latest:

Biliary Cancer: Current Multimodality Treatment and Future Directions

Clinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.


Crystal Denlinger, MD, FACP

Latest:

Therapy Options for Patients With Hepatocellular Carcinoma

Therapy options for patients with hepatocellular carcinoma (HCC), including a newly approved therapy for a subpopulation of patient.


Leanne Marcello, MS

Latest:

Patient Survival Rates in High-Grade Spinal Meningioma

Researchers recently looked at differences in survival time between patients with grade II and grade III spinal meningioma.



Ryan M. Phillips MD, PhD

Latest:

Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?

Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.


Matthew P. Deek, MD

Latest:

Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?

Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.


Benjamin Levy, MD

Latest:

OncView™ Podcast: Updates in Managing Extensive-Stage Small Cell Lung Cancer

This special edition of the “Oncology Peer Review On-The-Go” dives into recent updates and important treatment strategies for extensive-stage SCLC management.


Jennifer Crombie, MD

Latest:

Classifying DLBCL Subtypes for Optimal Treatment

Jennifer Crombie, MD, discusses classification of diffuse large B-cell lymphoma (DLBCL) into distinct subtypes and treatment decisions based on molecular classifications. 


Allison W. Kurian, MD

Latest:

Mutations and the Importance of Genetic Testing

Dr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.


Silas Inman

Latest:

Sonrotoclax/Zanubrutinib Combo Elicits Deep Responses for Untreated CLL/SLL

For patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.


Kristie L. Kahl

Latest:

42nd Annual Miami Breast Cancer Conference: The Show and After Show

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.


Brittany Lovely

Latest:

Sacituzumab Govitecan Combo Yields Early Activity in Metastatic NSCLC

Data from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.


Jason Williams, MD

Latest:

Jason Williams, MD, on Intratumoral Immunotherapy Advances at SITC 2019

Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).


Joshua Brody, MD

Latest:

Joshua Brody, MD, on Cross-Section of Science and Medicine at SITC 2019

Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).


Hannah Slater

Latest:

Experts Identify Steps to Improve Representation of African Americans in Multiple Myeloma Studies

“The importance of diverse representation cannot be underscored enough and is critical to ensure that safe and effective products are available to the [United States] patient population,” wrote the study authors, who were led by Nicole Gormley, MD.


Robert Ferris, MD

Latest:

Robert Ferris, MD, on Immunotherapy Transforming Cancer Treatment

Robert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.


Lara M. Bolaños, MD

Latest:

What Are the Most Common Esophageal Metastases

A rare occurrence, cancer in the esophagus requires an individualized treatment plan.


Sandip Patel, MD

Latest:

KRAS+ NSCLC: Treatment Management Strategies

This video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.